28002 Federal Register / Vol. 83, No. 116 / Friday, June 15, 2018 / Notices 

Conflict: Healthcare Delivery and 

Methodologies. 

Date: July 16, 2018. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Karin F. Helmers, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3166, 

MSC 7770, Bethesda, MD 20892, 301–254– 

9975, helmersk@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 8, 2018. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–12839 Filed 6–14–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Patent 

Commercialization License: 

Streptococcus Pneumonia PSAA 

Peptide for Treatment of Sepsis and 

Infection 

AGENCY: National Institutes of Health, 

Centers for Disease Control and 

Prevention, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Allergy and Infectious Diseases, an 

institute of the National Institutes of 

Health, Department of Health and 

Human Services, on behalf of the 

Centers for Disease Control and 

Prevention, Department of Health and 

Human Services, is contemplating the 

grant of an exclusive patent 

commercialization license to The 

University of Liverpool, located in 

Liverpool, UK, to practice the 

inventions embodied in the patent 

applications listed in the 

Supplementary Information section of 

this notice. 

DATES: Only written comments and/or 

applications for a license which are 

received by the Technology Transfer 

and Intellectual Property Office, 

National Institute of Allergy and 

Infectious Diseases on or before July 2, 

2018 will be considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

exclusive patent commercialization 

license should be directed to: Karen 

Surabian, Licensing and Patenting 

Manager, Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Suite 6D, 

MSC9804, Rockville, MD 20852–9804, 

phone number 301–496–2644, or 

karen.surabian@nih.gov. 

SUPPLEMENTARY INFORMATION: The 

following represents the intellectual 

property to be licensed under the 

prospective agreement: United States 

Provisional Patent Application Number 

61/085,208, filed 07/31/2008, entitled 

‘‘Methods of Enhancing 

Opsonophagocytosis in Response to a 

Pathogen’’ (HHS Reference No. E–329– 

2013/0–US–01); PCT Patent Application 

Number PCT/US2009/052384, filed 07/ 

31/2009, entitled ‘‘Methods of 

Enhancing Opsonophagocytosis in 

Response to a Pathogen’’ (HHS 

Reference No. E–329–2013/0–PCT–02); 

China Patent Number 200980137625.X, 

issued 11/26/2014, entitled ‘‘Methods of 

Enhancing Opsonophagocytosis in 

Response to a Pathogen’’ (HHS 

Reference No. E–329–2013/0–CN–03); 

European Patent Number 2323684, 

issued 05/21/2014, entitled ‘‘Use of a 

Pneumococcal P4 Peptide for Enhancing 

Opsonophagocytosis in Response to a 

Pathogen’’ (HHS Reference No. E–329– 

2013/0–EP–04), and validated in 

Germany, Spain, France, the United 

Kingdom, and Ireland; Hong Kong 

Patent Number 1160391, issued 07/31/ 

2015, entitled ‘‘Methods of Enhancing 

Opsonophagocytosis in Response to a 

Pathogen’’ (HHS Reference No. E–329– 

2013/0–HK–05); United States Patent 

Number 8,431,134, issued 04/30/2013, 

entitled ‘‘Use of a Pneumococcal P4 

Peptide for Enhancing 

Opsonophagocytosis in Response to a 

Pathogen’’ (HHS Reference No. E–329– 

2013/0–US–06); United States Patent 

Number 9,101,582, issued 08/11/2015, 

entitled ‘‘Use of a Pneumococcal P4 

Peptide for Enhancing 

Opsonophagocytosis in Response to a 

Pathogen’’ (HHS Reference No. E–329– 

2013/0–US–07); United States 

Provisional Patent Application Number 

60/682,495, filed 05/19/2005, entitled 

‘‘Functional Epitopes of Streptococcus 

Pneumonia PSAA Antigen and Uses 

Thereof’’ (HHS Reference No. E–338– 

2013/0–US–01); PCT Patent Application 

Number PCT/US2005/027290, filed 

07/29/2005, entitled ‘‘Functional 

Epitopes of Streptococcus Pneumonia 

PSAA Antigen and Uses Thereof’’ (HHS 

Reference No. E–338–2013/0–PCT–02); 

Australia Patent Number 2005332058, 

issued 03/15/2012, entitled ‘‘Functional 

Epitopes of Streptococcus Pneumonia 

PSAA Antigen and Uses Thereof’’ (HHS 

Reference No. E–338–2013/0–AU–03); 

European Patent Number 1931700, 

issued 07/17/2003, entitled ‘‘Functional 

Epitopes of Streptococcus Pneumonia 

PSAA Antigen and Uses Thereof’’ (HHS 

Reference No. E–338–2013/0–EP–04), 

and validated in: Germany, Spain, 

France, the United Kingdom, and 

Ireland; Hong Kong Patent Number 

1115144, issued 02/14/2014, entitled 

‘‘Functional Epitopes of Streptococcus 

Pneumonia PSAA Antigen and Uses 

Thereof’’ (HHS Reference No. E–338– 

2013/0–HK–05); United States Patent 

Number 7,919,104, issued 04/05/2011, 

entitled ‘‘Functional Epitopes of 

Streptococcus Pneumonia PSAA 

Antigen and Uses Thereof’’ (HHS 

Reference No. E–338–2013/0–US–06); 

Canada Patent Application Number 

2,631,556, filed 09/15/2014, entitled 

‘‘Functional Epitopes of Streptococcus 

Pneumonia PSAA Antigen and Uses 

Thereof’’ (HHS Reference No. E–338– 

2013/0–CA–07); Australia Patent 

Number 2012201107, issued 06/06/ 

2013, entitled ‘‘Functional Epitopes of 

Streptococcus Pneumonia PSAA 

Antigen and Uses Thereof’’ (HHS 

Reference No. E–338–2013/0–AU–08); 

Hong Kong Patent Number HK1163113, 

issued 06/05/2015, entitled ‘‘Functional 

Epitopes of Streptococcus Pneumonia 

PSAA Antigen and Uses Thereof’’ (HHS 

Reference No. E–338–2013/0–HK–09); 

European Patent Number 2371843, 

issued 09/17/2014, entitled ‘‘Functional 

Epitopes of Streptococcus Pneumonia 

PSAA Antigen and Uses Thereof’’ (HHS 

Reference No. E–338–2013/0–EP–10), 

and validated in: Germany, France, and 

the United Kingdom. 

All rights in these inventions have 

been assigned to the Government of the 

United States of America. 

The prospective exclusive patent 

commercialization license territory may 

be worldwide and the field of use may 

be limited to: ‘‘Development, 

manufacture, and sale of a P4 peptide 

therapeutic for the treatment of 

infection and sepsis.’’ 

These inventions, developed within 

the National Center for Immunization 

and Respiratory Diseases (NCIRD), at the 

Centers for Disease Control and 

Prevention (CDC), describe methods to 

bolster the human body’s own 

mechanisms to fight infection by 

enhancing an innate immune response, 

opsonophagocytosis. The specific 24 

amino acid peptide sequence (P4) acts 

as a polymorphonuclear cell activator. 

P4 can be administered in vivo along 

with disease-specific antibodies to 

enhance systemic bacterial clearance, 


sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 116 / Friday, June 15, 2018 / Notices 28003 

thus leading to prolonged survival. This 

technology enhances the body’s 

response to a variety of bacterial 

infections, including S. pneumoniae 

and S. aureus. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive patent 

commercialization license will be 

royalty bearing and may be granted 

unless within fifteen (15) days from the 

date of this published notice, the 

National Institute of Allergy and 

Infectious Diseases receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

Complete applications for a license in 

the prospective field of use that are 

timely filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive patent 

commercialization license. In response 

to this Notice, the public may file 

comments or objections. Comments and 

objections, other than those in the form 

of a license application, will not be 

treated confidentially, and may be made 

publicly available. License applications 

submitted in response to this Notice 

will be presumed to contain business 

confidential information, and any 

release of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: June 11, 2018. 

Suzanne M. Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2018–12838 Filed 6–14–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the joint meeting of the 

National Cancer Advisory Board and 

NCI Board of Scientific Advisors, June 

26, 2018, 8:30 a.m. to June 27, 2018, 

12:00 p.m., National Cancer Institute 

Shady Grove, 9609 Medical Center 

Drive, Conference Room TE 406/408, 

Rockville, MD 20850 which was 

published in the Federal Register on 

June 05, 2018, 83 FR 26069. 

This meeting notice is being amended 

to update the meeting locations for the 

National Cancer Advisory Board Ad Hoc 

Subcommittee meetings. The National 

Cancer Advisory Board Ad Hoc 

Subcommittee Population Science, 

Epidemiology and Disparities meeting 

on June 25, 2018, 5:30 p.m. to 7:30 p.m., 

will be held at the Gaithersburg Marriott 

Washingtonian Center in Salons A and 

B. The National Cancer Advisory Board 

Ad Hoc Subcommittee on Global Cancer 

Research meeting on June 25, 2018, 7:30 

p.m. to 9:00 p.m., will be held at the 

Gaithersburg Marriott Washingtonian 

Center in Salon C. 

Dated: June 11, 2018. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–12837 Filed 6–14–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–1243. 

Project: Survey of State Underage 

Drinking Prevention Policies and 

Practices—(OMB No. 0930–0316)— 

Revision 

The Sober Truth on Preventing 

Underage Drinking Act (the ‘‘STOP 

Act’’) (Pub. L. 109–422, reauthorized in 

2016 by Pub. L. 114–255) states that the 

‘‘Secretary [of Health and Human 

Services] shall . . . annually issue a 

report on each state’s performance in 

enacting, enforcing, and creating laws, 

regulations, and programs to prevent or 

reduce underage drinking.’’ The 

Secretary has delegated responsibility 

for this report to SAMHSA. Therefore, 

SAMHSA has developed a Survey of 

State Underage Drinking Prevention 

Policies and Practices (the ‘‘State 

Survey’’) to provide input for the stateby-state report on prevention and 

enforcement activities related to 

underage drinking component of the 

Annual Report to Congress on the 

Prevention and Reduction of Underage 

Drinking (‘‘Report to Congress’’). 

The STOP Act also requires the 

Secretary to develop ‘‘a set of measures 

to be used in preparing the report on 

best practices’’ and to consider 

categories including but not limited to 

the following: 

Category #1: Sixteen specific 

underage drinking laws/regulations 

enacted at the state level (e.g., laws 

prohibiting sales to minors; laws related 

to minors in possession of alcohol). 

Note that ten additional policies have 

been added to the Report to Congress 

pursuant to Congressional 

appropriations language or the 

Secretary’s authority granted by the 

STOP Act; 

Category #2: Enforcement and 

educational programs to promote 

compliance with these laws/regulations; 

Category #3: Programs targeted to 

youths, parents, and caregivers to deter 

underage drinking and the number of 

individuals served by these programs; 

Category #4: The amount that each 

state invests, per youth capita, on the 

prevention of underage drinking broken 

into five categories: (a) Compliance 

check programs in retail outlets; (b) 

Checkpoints and saturation patrols that 

include the goal of reducing and 

deterring underage drinking; (c) 

Community-based, school-based, and 

higher-education-based programs to 

prevent underage drinking; (d) 

Underage drinking prevention programs 

that target youth within the juvenile 

justice and child welfare systems; and 

(e) Any other state efforts or programs 

that target underage drinking. 

Congress’ purpose in mandating the 

collection of data on state policies and 

programs through the State Survey is to 

provide policymakers and the public 

with otherwise unavailable but much 

needed information regarding state 

underage drinking prevention policies 

and programs. SAMHSA and other 

Federal agencies that have underage 

drinking prevention as part of their 

mandate use the results of the State 

Survey to inform federal programmatic 

priorities, as do other stakeholders, 

including community organizations. 

The information gathered by the State 

Survey has established a resource for 

state agencies and the general public for 

assessing policies and programs in their 

own state and for becoming familiar 

with the programs, policies, and 

funding priorities of other states. 

Because of the broad scope of data 

required by the STOP Act, SAMHSA 

relies on existing data sources where 

possible to minimize the survey burden 

on the states. SAMHSA uses data on 

state underage drinking policies from 

the National Institute of Alcohol Abuse 

and Alcoholism’s Alcohol Policy 

Information System (APIS), an 

authoritative compendium of state 


sradovich on DSK3GMQ082PROD with NOTICES